EC
JAZZ icon

EcoR1 Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

EcoR1 Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,706,469
Closed -$323M – 38
2026
Q1 		$323M Hold
1,706,469
– – 13.69% 3
2025
Q4 		$290M Hold
1,706,469
– – 13.16% 3
2025
Q3 		$225M Hold
1,706,469
– – 10.79% 4
2025
Q2 		$181M Hold
1,706,469
– – 10.72% 3
2025
Q1 		$212M Hold
1,706,469
– – 12.57% 2
2024
Q4 		$210M Hold
1,706,469
– – 7.95% 4
2024
Q3 		$190M Buy
1,706,469
+692,517
+68% +$75.9M 6.51% 5
2024
Q2 		$108M Hold
1,013,952
– – 3.31% 12
2024
Q1 		$122M Hold
1,013,952
– – 3.09% 10
2023
Q4 		$125M Buy
1,013,952
+645,541
+175% +$80.6M 3.24% 10
2023
Q3 		$47.7M Hold
368,411
– – 1.61% 14
2023
Q2 		$45.7M Buy
+368,411
New +$49.6M 1.12% 17

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

EcoR1 Capital's JAZZ Position: Q2 2026 in Review

EcoR1 Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2026, closing a stake of 1,706,469 shares — an estimated $323M sold.

EcoR1 Capital first reported a position in JAZZ in Q2 2023 and held it in 12 quarters. The position peaked at $323M in Q1 2026. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • EcoR1 Capital reported no remaining Jazz Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • EcoR1 Capital sold 1,706,469 Jazz Pharmaceuticals shares in Q2 2026, an estimated $323M.
  • EcoR1 Capital first reported a position in Jazz Pharmaceuticals in Q2 2023 and held it in 12 quarters.
  • EcoR1 Capital's Jazz Pharmaceuticals position peaked at $323M in Q1 2026.
  • 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on EcoR1 Capital's 13F filing for Q2 2026, filed 14 Aug 2026.